Doximity Inc. (NYSE:DOCS) is considered an oversold stock to buy now, with Morgan Stanley upgrading the company to Overweight and increasing the price target to $65 on December 15. Barclays analyst Glen Santangelo also initiated coverage with an Overweight rating and a $63 price target on December 8, highlighting the company’s strong user engagement and AI integration.

The company’s focus on AI has led to a significant increase in user engagement, with AI Scribe users nearly tripling between FQ1 2026 and FQ2 2026. The integration of Pathway’s medical data sets and AI models into the DoxGPT feature has been successful, resulting in a 50% increase in AI-related Quality Adjusted Users/QAUs quarter-over-quarter.

Doximity Inc. (NYSE:DOCS) operates as a digital platform for medical professionals in the US. While the company shows promise as an investment, there are other AI stocks with potentially greater upside and less downside risk, especially in light of current market trends.

For more information on potential investment opportunities, visit Insider Monkey for detailed reports and analysis on stocks with growth potential. No disclosures were made in this article.

Read more at Yahoo Finance: Morgan Stanley Views Doximity (DOCS) Underperformance as Attractive Entry Point Amid Strong Engagement